![]() Sara provides clinical and scientific expertise for Abbott’s adult nutrition products and specializes in diabetes and oncology. Sara Thomas, PhD, RD is a registered dietitian and a research scientist supporting the Global Science team at Abbott. ![]() Sara Thomas, PhD, RD, registered dietician and research scientist at Abbott, discusses a new study from Abbott and The Ohio State University that was published in "Nutrients" that showed that adults with diabetes with low protein leads to physical limitations, lower overall diet quality, poorer nutrition density and more carbohydrates consumed. ![]() Joyce testified before Congress and lobbied Capitol Hill to promote the Hemopurifier® as a broad-spectrum countermeasure against bioterror and pandemic threats, which contributed to expanding the government-wide definition of treatment countermeasure to be inclusive of medical devices under U.S. Joyce was the recipient of the “Spirit of India Award” sponsored by the Bill & Melinda Gates Foundation and awarded each year by the American India Foundation to the American business leader who has demonstrated a commitment to accelerate social and economic change in India. Joyce led the completion of approximately $100 million of equity financings on behalf of Aethlon Medical and established preclinical and clinical collaborations with more than twenty government and non-government research institutes.īased on the use of the Hemopurifier® to treat HIV and Hepatitis-C infected individuals in India, Mr. Joyce’s leadership, the Hemopurifier® was the subject of two Department of Defense (DOD) contract awards and a National Cancer Institute (NCI) contract. The Hemopurifier® has since been cleared by the FDA to treat severe COVID-19 infections in a clinical setting. Time Magazine named the Hemopurifier® one of the “11 Most Remarkable Advances in Healthcare” and designated the device to its “Top 25 Best Inventions” award list. Under his leadership, the Hemopurifier® became the first therapeutic candidate to be awarded two FDA “Breakthrough Device” designations and was the first and only device to receive “Emergency Use Authorization” (EAU) approval from both the FDA and Health Canada to treat Ebola virus. Joyce oversaw the development of the Hemopurifier®, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technology company that he navigated from single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders. Prior to establishing Sigyn Therapeutics, Mr. He is also an inventor or co-inventor underlying 18 pending or issued patents. James “Jim” Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. #SigynTherapeutics #BloodPurificationTechnology #CytokineStorm He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company's blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |